medicine-products/replacement-bulb-3a--uxl-150m-o-7352-1/;+health+history;+medical+history.html

Breaking Biology Technology:Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6 MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 2 MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 3 MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 4 CSOFT's MedL10N Hires Beckman Coulter Veteran Tammy Werner 2 CSOFT's MedL10N Hires Beckman Coulter Veteran Tammy Werner 3 Dendreon Announces Proposed Public Offering of Common Stock 2 Dendreon Announces Proposed Public Offering of Common Stock 3

[0] Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain [0] MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products [0] CSOFT's MedL10N Hires Beckman Coulter Veteran Tammy Werner [0] Dendreon Announces Proposed Public Offering of Common Stock

Breaking Medicine Technology:Dynatronics Receives 180-Day NASDAQ Extension 2 Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2 Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3 Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2 Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3 U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 1 U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 2 U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 3 U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 4 U S Food and Drug Administration Clears Vermillions OVA1 28TM 29 Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 56963 5 West to Present at Two Upcoming Investor Conferences 56960 1 West to Present at Two Upcoming Investor Conferences 56960 2 Early results from clinical trials of 2009 H1N1 influenza vaccines in healthy adults 56959 1 Early results from clinical trials of 2009 H1N1 influenza vaccines in healthy adults 56959 2

[0] Dynatronics Receives 180-Day NASDAQ Extension [0] Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug [0] Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign